MORPHIC HOLDING INC (MORF)
US61775R1059 - Common Stock
Morphic to Participate in RBC Capital Markets Global Healthcare Conference
MORF Stock Earnings: Morphic Holding Beats EPS for Q1 2024
MORF stock results show that Morphic Holding beat analyst estimates for earnings per share the first quarter of 2024.
MORF Stock Earnings: Morphic Holding Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Morphic Holding (NASDAQ:MORF) just reported results for the first quarter of 20...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
MORF ends 1Q24 with $659 million, cash into 2H27; phase 2b study of MORF-057 in UC continues on target; anticipate GARNET phase 2 in Crohn's to begin 2Q...
Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.
/PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Morphic (NASDAQ: MORF). The investigation results from inaccurate...
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
MORF Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Morphic Holding, Inc. (NASDAQ:MORF)
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases...
Commit To Buy Morphic Holding At $20, Earn 10.9% Annualized Using Options
Morphic to Participate in March Investor Conferences
Morphic to Participate in March Investor Conferences
WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
MORF ends '23 with $700 million, cash into 2H27; MORF-057 EMERALD-2 UC trial enrolling on target; to begin Ph 2 GARNET trial of 057 in Crohn's disease...
Bullish Two Hundred Day Moving Average Cross - MORF
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
The Law Offices of Frank R. Cruz Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Morphic CEO. Praveen Tipirneni, MD, to present at JP Morgan Healthcare Conference January 10, 2024...
Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors
Morphic to Present at November Investor Conferences
Morphic GAAP EPS of -$0.73 beats by $0.22 (NASDAQ:MORF)
Morphic (MORF) beats expectations with a Q3 GAAP EPS of -$0.73, surpassing estimates by $0.22.
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on...
NASDAQ: MORF Investor Notice: Investigation over Possible Securities Laws Violations by Morphic Holding, Inc.
San Diego, CA -- (SBWIRE) -- 11/01/2023 -- Morphic Holding, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Commit To Purchase Morphic Holding At $15, Earn 17.9% Annualized Using Options
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...
Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...
MORF INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral...
